🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out our recent paper comparing the tau PET tracers 18F-MK6240 and flortaucipir published in jpreventionalzheimer, a study led by Dr Bourgeat from CSIRO #Alzheimer

Are you looking for a postdoc position in an awesome lab? Come join us! Buckley lab is seeking a postdoc (summer start, negotiable) that will work on a large multi-cohort project investigating resistance and resilience to Alzheimer's disease! bitly.ws/BC3V #postdocjobs

Privileged to have had the Victorian minister for health, infrastructure and medical research, Mary-Anne Thomas MP visit The Florey to hear about all the exciting projects, including our brain PET dementia research #dementia #Alzheimer

Amyloid PET brain imaging is a valuable diagnostic tool for detecting early signs of dementia, Alzheimer's disease and MCI. In this 2 part series, Prof Chris Rowe explains appropriate use of amyloid PET, how to read scans & accurately interpret results buff.ly/3UB2Vjx

Universal sampling masks for tau imaging (CenTauR) are now available for download on #GAAIN: gaain.org/centaur-project

Excited for Day 2 of #ADRF2023 don’t miss the presentation on prognostic utility of plasma p217+tau vs amyloid and tau PET -oral discovery session at 11.20 Azadeh Feizpour @ADRF2023

Enjoying day #2 of the #AAIC2023 in Amsterdam with Christopher Rowe , Vincent Dore , Natasha Krishnadas , Azadeh Feizpour and Marj, but would like to acknowledge the many of our hard-working team members back in Melbourne that are missing from this photo.

Come check out the poster by Azadeh Feizpour at site 252 to know more about plasma p217+tau and how it compares to amyloid and tau PET #AAIC2023

We’re in dire need of a standardised scale for quantification of tau PET. Drop by the poster by Vincent Dore at site 361 to know more about the CenTauR scale. #AAIC2023

🔥 Hot off the press: our new article on VMAT2 PET as a sensitive tool to detect and quantify Parkinson’s disease (PD) progression over two years.🧠 This is a breakthrough discovery with implications for PD diagnostics and clinical trials. #Neuroscience #Parkinsons

Exciting results!🧠✨Our latest study showcases that plasma P217+tau can distinguish Intermediate or Advanced stage #Alzheimer's, defined based on the 2023 biological PET staging scheme. Dive into the details in our preprint: medrxiv.org/content/10.110… #AlzheimersResearch

Trials are currently in progress for #Alzheimer's blood tests in Australia. Tune in to our interview on 7NEWS Melbourne to stay informed and contribute to the journey against Alzheimer's. #Alzheimers #Research #Dementia #DementiaAwareness

🌊🏄‍♀️ Exciting news! A postdoctoral opportunity is now available in my team in Melbourne! Join us and contribute to cutting-edge research in imaging the aging brain. #postdocopportunity #scienceAustralia 🏖️🐨🦘 jobs.csiro.au/job/Melbourne%…

Don't miss out on the opportunity to join our team! The final day (21st) to apply for this postdoc position is fast approaching. #AlzheimersDisease #NeuroImaging #BrainScience #AlzheimerResearch #Neuroscience #ClinicalTrials #jobopening #careerdevelopment

We at Rowe Lab are very proud that our PET expert, Vincent Dore was awarded the prestigious de Leon Prize, as senior author of “CenTauR: Toward a universal scale and masks for standardizing tau imaging studies”. Time to celebrate this great achievement! #AAIC24 #AIC

Exciting news! Our findings on the Lumipulse #pTau217 assay were featured in Herald Sun and The Daily Telegraph. In this interview, Prof. Christopher Rowe explains the difference this blood test could make for #Alzheimers diagnosis. Have a read here: dailytelegraph.com.au/news/victoria/…